PE20040893A1 - DERIVADOS DE INDOL O DERIVADOS DE BENCIMIDAZOL PARA MODULAR IkB QUINASA - Google Patents
DERIVADOS DE INDOL O DERIVADOS DE BENCIMIDAZOL PARA MODULAR IkB QUINASAInfo
- Publication number
- PE20040893A1 PE20040893A1 PE2003000772A PE2003000772A PE20040893A1 PE 20040893 A1 PE20040893 A1 PE 20040893A1 PE 2003000772 A PE2003000772 A PE 2003000772A PE 2003000772 A PE2003000772 A PE 2003000772A PE 20040893 A1 PE20040893 A1 PE 20040893A1
- Authority
- PE
- Peru
- Prior art keywords
- derivatives
- alkyl
- benzhimidazole
- modular
- ikb kinase
- Prior art date
Links
- 108091000080 Phosphotransferase Proteins 0.000 title abstract 2
- 102000020233 phosphotransferase Human genes 0.000 title abstract 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical class C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 title 1
- 229940054051 antipsychotic indole derivative Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical compound C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 abstract 2
- -1 4-FLUOROPHENYL Chemical class 0.000 abstract 1
- 208000036487 Arthropathies Diseases 0.000 abstract 1
- 208000012659 Joint disease Diseases 0.000 abstract 1
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical group C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
Abstract
SE REFIERE A UN COMPUESTO DE FORMULA I DONDE X Y M SON CADA UNO N, CH; R1 Y R11 SON CADA UNO H, HALOGENO, ALQUILO C1-C4, -CN, ENTRE OTROS; R2 ES HETEROARILO, -COOH, -COO(ALQUILO C1-C4), ENTRE OTROS; R3 ES H, ALQUILO C1-C4; R4 ES ARILO O HETEROARILO DEL GRUPO PIRROL, FURANO, TIOFENO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: N-[(S)-2-DIFENILAMINO-1-(5-OXO-4,5-DIHIDRO[1,3,4]OXADIAZOL-2-IL)ETIL]-2-(2-METILAMINOPIRIMIDIN-4-IL)-1H-INDOL-5-CARBOXAMIDA Y N-{1-CARBAMOIL-2-[(4-FLUOROFENIL)PIRIDIN-2-ILAMINO]ETIL}-2-(2-METILAMINOPIRIMIDIN-4-IL)-1H-INDOL-5-CARBOXAMIDA; ENTRE OTROS. SE REFIERE TAMBIEN A UN PRODUCTO FARMACEUTICO EN EL CUAL DICHOS COMPUESTOS SON INHIBIDORES DE IkB QUINASA UTILES EN EL TRATAMIENTO DE ARTRITIS REUMATOIDE, ARTROPATIAS OSTEOARTRITIS, DIABETES TIPO II, ENTRE OTROS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10237722A DE10237722A1 (de) | 2002-08-17 | 2002-08-17 | Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20040893A1 true PE20040893A1 (es) | 2004-12-21 |
Family
ID=31968974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2003000772A PE20040893A1 (es) | 2002-08-17 | 2003-08-05 | DERIVADOS DE INDOL O DERIVADOS DE BENCIMIDAZOL PARA MODULAR IkB QUINASA |
Country Status (42)
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19951360A1 (de) * | 1999-10-26 | 2001-05-03 | Aventis Pharma Gmbh | Substituierte Indole |
| DE10237723A1 (de) * | 2002-08-17 | 2004-07-08 | Aventis Pharma Deutschland Gmbh | Verwendung von IKappaB-Kinase Inhibitoren in der Schmerztherapie |
| DE10237722A1 (de) * | 2002-08-17 | 2004-08-19 | Aventis Pharma Deutschland Gmbh | Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase |
| HRP20050696B1 (en) | 2003-01-14 | 2008-10-31 | Arena Pharmaceuticals Inc. | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
| AR045047A1 (es) * | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
| JP2007537266A (ja) * | 2004-05-12 | 2007-12-20 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | ＩκＢキナーゼ阻害剤として実質的に純粋な２−｛［２−（２−メチルアミノ−ピリミジン−４−イル）−１Ｈ−インドール−５−カルボニル］−アミノ｝−３−（フェニルピリジン−２−イル−アミノ）−プロピオン酸 |
| AR050253A1 (es) | 2004-06-24 | 2006-10-11 | Smithkline Beecham Corp | Compuesto derivado de indazol carboxamida, composicion que lo comprende y su uso para la preparacion de un medicamento |
| DE102004033406A1 (de) * | 2004-07-10 | 2006-02-16 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Herstellung der enantiomeren Formen von 2,3-Diaminopropionsäurederivaten |
| PE20060748A1 (es) | 2004-09-21 | 2006-10-01 | Smithkline Beecham Corp | Derivados de indolcarboxamida como inhibidores de quinasa ikk2 |
| DOP2006000010A (es) * | 2005-01-10 | 2006-07-31 | Arena Pharm Inc | Procedimiento para preparar eteres aromáticos |
| WO2006076318A1 (en) * | 2005-01-12 | 2006-07-20 | Aventis Pharmaceuticals Inc. | Monopotassium salt of an ikb kinase inhibitor |
| US20070142417A1 (en) * | 2005-05-11 | 2007-06-21 | Aventis Pharmaceuticals Inc | Substantially Pure 2-{[2-(2-Methylamino-Pyrimidin-4-YL)-1H-Indole-5-Carbonyl]-Amino}-3-Phenylpyridin-2-YL-Amino)-Propionic Acid as an IkB Kinase Inhibitor |
| DE102005025225A1 (de) | 2005-06-01 | 2006-12-07 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Herstellung von 2-(2-Amino-pyrimidin-4-yl)-1H-indol-5-carbonsäure-derivaten |
| CN101247804B (zh) | 2005-06-30 | 2012-09-26 | 史密丝克莱恩比彻姆公司 | 化学化合物 |
| US8063071B2 (en) | 2007-10-31 | 2011-11-22 | GlaxoSmithKline, LLC | Chemical compounds |
| US8088928B2 (en) * | 2005-08-04 | 2012-01-03 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| US7855289B2 (en) * | 2005-08-04 | 2010-12-21 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| EP2468752A1 (en) * | 2005-08-04 | 2012-06-27 | Sirtris Pharmaceuticals, Inc. | Thiazolopyridine derivatives as sirtuin-modulators |
| US8093401B2 (en) * | 2005-08-04 | 2012-01-10 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| CA2621057A1 (en) | 2005-09-07 | 2007-03-15 | Laboratoires Serono S.A. | Ikk inhibitors for the treatment of endometriosis |
| JP2009001495A (ja) * | 2005-10-13 | 2009-01-08 | Taisho Pharmaceutical Co Ltd | ２−アリール−ベンゾイミダゾール−５−カルボキサミド誘導体 |
| CA2666193A1 (en) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use |
| AR065804A1 (es) | 2007-03-23 | 2009-07-01 | Smithkline Beecham Corp | Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento |
| CL2008001822A1 (es) * | 2007-06-20 | 2009-03-13 | Sirtris Pharmaceuticals Inc | Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras. |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| CN101784543B (zh) * | 2007-08-17 | 2013-10-16 | 株式会社Lg生命科学 | 作为细胞坏死抑制剂的吲哚和吲唑化合物 |
| BRPI0819093A2 (pt) * | 2007-11-01 | 2017-05-02 | Sirtris Pharmaceuticals Inc | compostos moduladores de sirtuína |
| AU2008325148A1 (en) * | 2007-11-08 | 2009-05-14 | Sirtris Pharmaceuticals, Inc. | Solubilized thiazolopyridines |
| UY31968A (es) | 2008-07-09 | 2010-01-29 | Sanofi Aventis | Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| MY160006A (en) | 2008-12-19 | 2017-02-15 | Sirtris Pharmaceuticals Inc | Thiazolopyridine sirtuin modulating compounds |
| MX2011008982A (es) * | 2009-02-27 | 2011-09-15 | Enata Pharmaceuticals Inc | Inhibidores del virus de la hepatitis c. |
| WO2010102968A1 (en) | 2009-03-10 | 2010-09-16 | Glaxo Group Limited | Indole derivatives as ikk2 inhibitors |
| MX2012001729A (es) | 2009-08-26 | 2012-06-13 | Sanofi Sa | Nuevos hidratos cristalinos de fluoroglicosido heteroaromatico, productos farmaceuticos que comprenden estos compuestos, y su empleo. |
| ES2937386T3 (es) | 2010-01-27 | 2023-03-28 | Arena Pharm Inc | Procesos para la preparación de ácido (R)-2-(7-(4-ciclopentil-3-(trifluorometil)benciloxi)-1,2,3,4-tetrahidrociclopenta[b]indol-3-il)acético y sales del mismo |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| AU2010351938B2 (en) * | 2010-04-27 | 2014-10-30 | Hutchison Medipharma Limited | Pyrimidinyl indole compounds |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| BR112013002985A2 (pt) * | 2010-08-12 | 2017-11-07 | Sanofi Sa | processo para a preparação de formas enantiométrica de derivados de ácido 2,3-diaminopropiônico |
| CN103221410B (zh) | 2010-09-22 | 2017-09-15 | 艾尼纳制药公司 | Gpr119受体调节剂和对与其相关的障碍的治疗 |
| JP5790440B2 (ja) * | 2010-12-01 | 2015-10-07 | 住友化学株式会社 | ピリミジン化合物およびその有害生物防除用途 |
| US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| US8895547B2 (en) | 2011-03-08 | 2014-11-25 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
| WO2012120051A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120058A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683702B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2683700B1 (de) | 2011-03-08 | 2015-02-18 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| ES2564671T3 (es) | 2011-07-27 | 2016-03-28 | Astrazeneca Ab | Compuestos de 2-(2,4,5-anilino sustituido)pirimidina |
| US9416124B2 (en) * | 2011-08-25 | 2016-08-16 | St. Jude Children's Research Hospital | Substituted 2-alkyl-1-OXO-N-phenyl-3-heteroaryl-1,2,3,4-tetrahydroisoquinoline-4-carboxamides for antimalarial therapies |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| DK2787998T3 (en) * | 2011-12-06 | 2017-02-06 | Sanofi Sa | Crystalline Forms of 2- (2-METHYLAMINOPYRIMIDIN-4-YL) -1H-INDOL-5-CARBOXYLIC ACID - [(S) -1-CARBAMOYL-2- (PHENYLPYRIMIDIN-2-YLAMINO) -ETHYL] -AMIDE |
| EA036521B1 (ru) * | 2012-01-27 | 2020-11-19 | Астразенека Аб | Производные 2-(2,4,5-замещенного анилино)пиримидина в качестве модуляторов egfr, полезных для лечения рака |
| KR101493877B1 (ko) | 2013-03-29 | 2015-02-16 | 농업회사법인 주식회사 생명의나무 | 스피나스테롤 당 유도체를 포함하는 골 질환 예방 또는 치료용 약학 조성물 |
| EP2805705B1 (en) | 2013-05-23 | 2016-11-09 | IP Gesellschaft für Management mbH | Packaging with one or more administration units comprising a sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1 H-imidazol-4-yl)-propionic acid |
| EP2905282A1 (en) * | 2014-02-05 | 2015-08-12 | AXXAM S.p.A. | Substituted thiazole or oxazole as P2X7 receptor antagonists |
| CA2951972A1 (en) * | 2014-07-03 | 2016-01-07 | Sanofi | 2-(2-methylamino-pyrimidin-4-yl)-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide for use in the treatment of pain associated to osteoarthritis |
| UA126268C2 (uk) | 2015-01-06 | 2022-09-14 | Арена Фармасьютікалз, Інк. | СПОСОБИ ЛІКУВАННЯ СТАНІВ, ПОВ'ЯЗАНИХ З РЕЦЕПТОРОМ S1P<sub>1 </sub> |
| MA42807A (fr) | 2015-06-22 | 2018-07-25 | Arena Pharm Inc | Sel l-arginine cristallin d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclo-penta[b]indol-3-yl)acétique (composé 1) pour une utilisation dans des troubles associés au récepteur de s1p1 |
| EP3290416A1 (en) * | 2016-08-31 | 2018-03-07 | AXXAM S.p.A. | Substituted n-[2-(4-phenoxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamide and n-[2-(4-benzyloxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamide derivatives and their use as p2x7 receptor antagonist |
| CN106588803A (zh) * | 2016-11-16 | 2017-04-26 | 西南科技大学 | 一种制备5‑乙酰基异噁唑的新方法 |
| CN108299302A (zh) * | 2017-01-11 | 2018-07-20 | 西南科技大学 | 一种制备3-乙酰基吡唑的新方法 |
| MA47504A (fr) | 2017-02-16 | 2019-12-25 | Arena Pharm Inc | Composés et méthodes de traitement de l'angiocholite biliaire primitive |
| KR102859841B1 (ko) | 2018-06-06 | 2025-09-12 | 아레나 파마슈티칼스, 인크. | S1p1 수용체와 관련된 병태의 치료 방법 |
| CA3133766A1 (en) | 2019-03-29 | 2020-10-08 | Astrazeneca Ab | Osimertinib for use in the treatment of non-small cell lung cancer |
| WO2021154902A1 (en) * | 2020-01-30 | 2021-08-05 | Anima Biotech Inc. | Collagen 1 translation inhibitors and methods of use thereof |
| CN115974849B (zh) * | 2022-12-28 | 2024-06-21 | 中国药科大学 | 一种吲哚氧乙酰胺类衍生物、包含其的药物组合物及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE156823T1 (de) * | 1990-06-07 | 1997-08-15 | Zeneca Ltd | Therapeutische heterocyclische verbindungen |
| AU675680B2 (en) | 1992-10-14 | 1997-02-13 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| GB9225141D0 (en) | 1992-12-01 | 1993-01-20 | Smithkline Beecham Corp | Chemical compounds |
| IT1275433B (it) * | 1995-05-19 | 1997-08-07 | Smithkline Beecham Farma | Derivati di diarildiammine |
| FR2763337B1 (fr) * | 1997-05-13 | 1999-08-20 | Sanofi Sa | Nouveaux derives du triazole, un procede pour leur preparation et compositions pharmaceutiques les contenant |
| NZ516348A (en) * | 1999-06-23 | 2003-06-30 | Aventis Pharma Gmbh | Substituted benzimidazole |
| DE19951360A1 (de) * | 1999-10-26 | 2001-05-03 | Aventis Pharma Gmbh | Substituierte Indole |
| JP2004529088A (ja) | 2001-02-01 | 2004-09-24 | ブリストル−マイヤーズ スクイブ カンパニー | ＩｋＢキナーゼ（ＩＫＫ）のインヒビターを用いる炎症性および免疫疾患の処置法 |
| DE10237723A1 (de) * | 2002-08-17 | 2004-07-08 | Aventis Pharma Deutschland Gmbh | Verwendung von IKappaB-Kinase Inhibitoren in der Schmerztherapie |
| US7462638B2 (en) * | 2002-08-17 | 2008-12-09 | Sanofi-Aventis Deutschland Gmbh | Use of IκB-kinase inhibitors in pain therapy |
| DE10237722A1 (de) * | 2002-08-17 | 2004-08-19 | Aventis Pharma Deutschland Gmbh | Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase |
| US7046741B2 (en) * | 2004-04-16 | 2006-05-16 | Data Flow Technologies, Inc. | Single and multiple sinewave modulation and demodulation techniques, apparatus, and communications systems |
-
2002
- 2002-08-17 DE DE10237722A patent/DE10237722A1/de not_active Withdrawn
-
2003
- 2003-05-08 UA UAA200502387A patent/UA78591C2/uk unknown
- 2003-07-23 JO JO200387A patent/JO2764B1/en active
- 2003-08-05 SI SI200331971T patent/SI1530568T1/sl unknown
- 2003-08-05 PL PL03374229A patent/PL374229A1/xx unknown
- 2003-08-05 DE DE50313372T patent/DE50313372D1/de not_active Expired - Lifetime
- 2003-08-05 MX MXPA05001314A patent/MXPA05001314A/es active IP Right Grant
- 2003-08-05 SI SI200332173T patent/SI2233483T1/sl unknown
- 2003-08-05 RU RU2005107418/04A patent/RU2318820C2/ru not_active IP Right Cessation
- 2003-08-05 PT PT03793685T patent/PT1530568E/pt unknown
- 2003-08-05 CA CA2498559A patent/CA2498559C/en not_active Expired - Fee Related
- 2003-08-05 AT AT03793685T patent/ATE493402T1/de active
- 2003-08-05 RS YU20050104A patent/RS51902B/sr unknown
- 2003-08-05 EP EP10163200A patent/EP2233483B1/de not_active Expired - Lifetime
- 2003-08-05 OA OA1200500047A patent/OA12908A/en unknown
- 2003-08-05 JP JP2004533319A patent/JP4504812B2/ja not_active Expired - Fee Related
- 2003-08-05 PE PE2003000772A patent/PE20040893A1/es not_active Application Discontinuation
- 2003-08-05 AU AU2003263196A patent/AU2003263196B2/en not_active Ceased
- 2003-08-05 ME MEP-606/08A patent/MEP60608A/xx unknown
- 2003-08-05 HR HRP20050042AA patent/HRP20050042B1/hr not_active IP Right Cessation
- 2003-08-05 EP EP03793685A patent/EP1530568B1/de not_active Expired - Lifetime
- 2003-08-05 AT AT10163200T patent/ATE557018T1/de active
- 2003-08-05 NZ NZ538296A patent/NZ538296A/en not_active IP Right Cessation
- 2003-08-05 CN CNB038195437A patent/CN1314683C/zh not_active Expired - Fee Related
- 2003-08-05 ES ES03793685T patent/ES2358795T3/es not_active Expired - Lifetime
- 2003-08-05 BR BRPI0313562-4A patent/BR0313562A/pt not_active Application Discontinuation
- 2003-08-05 ES ES10163200T patent/ES2387954T3/es not_active Expired - Lifetime
- 2003-08-05 PT PT10163200T patent/PT2233483E/pt unknown
- 2003-08-05 KR KR1020057002707A patent/KR101162046B1/ko not_active Expired - Fee Related
- 2003-08-05 DK DK03793685.3T patent/DK1530568T3/da active
- 2003-08-05 DK DK10163200.8T patent/DK2233483T3/da active
- 2003-08-05 WO PCT/EP2003/008629 patent/WO2004022553A1/de not_active Ceased
- 2003-08-12 PA PA20038580501A patent/PA8580501A1/es unknown
- 2003-08-14 TW TW092122309A patent/TWI290552B/zh not_active IP Right Cessation
- 2003-08-14 AR ARP030102946A patent/AR040975A1/es not_active Application Discontinuation
- 2003-08-15 MY MYPI20033115A patent/MY140074A/en unknown
- 2003-08-15 SV SV2003001599A patent/SV2004001599A/es unknown
- 2003-08-15 HN HN2003000249A patent/HN2003000249A/es unknown
- 2003-08-15 UY UY27941A patent/UY27941A1/es unknown
- 2003-08-18 US US10/642,970 patent/US7285560B2/en not_active Expired - Lifetime
-
2005
- 2005-01-13 ZA ZA200500322A patent/ZA200500322B/en unknown
- 2005-01-28 CR CR7668A patent/CR7668A/es unknown
- 2005-02-09 IL IL16678505A patent/IL166785A0/xx not_active IP Right Cessation
- 2005-02-15 MA MA28106A patent/MA27382A1/fr unknown
- 2005-02-15 CO CO05013335A patent/CO5690586A2/es active IP Right Grant
- 2005-02-16 TN TNP2005000045A patent/TNSN05045A1/en unknown
- 2005-02-17 EC EC2005005612A patent/ECSP055612A/es unknown
- 2005-03-15 NO NO20051337A patent/NO330981B1/no not_active IP Right Cessation
-
2007
- 2007-06-06 US US11/758,978 patent/US8778955B2/en not_active Expired - Fee Related
-
2011
- 2011-03-02 CY CY20111100246T patent/CY1111692T1/el unknown
-
2012
- 2012-07-24 CY CY20121100658T patent/CY1112991T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20040893A1 (es) | DERIVADOS DE INDOL O DERIVADOS DE BENCIMIDAZOL PARA MODULAR IkB QUINASA | |
| DE60228406D1 (de) | PYRAZOLOÄ3,4-dÜPYRIMIDINDERIVATE UND IHRE VERWENDUNG ALS ANTAGONISTEN DES PURINERGEN REZEPTORS | |
| RU2009115963A (ru) | Производные оксадиазола, обладающие противовоспалительными и иммунодепрессантными свойствами | |
| PE20030940A1 (es) | Derivados de piridina y pirimidina | |
| CO5700824A2 (es) | Nuevos compuestos heterociclicos utiles para el tratamiento de desordenes inflamatorios y alergicos: proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| CO5550421A2 (es) | Derivados de indol utiles para el tratamiento de enfermeda- des | |
| AR058403A1 (es) | PIRIMIDINILOXI Y PIRIDINILOXI UREAS SUSTITUíDAS COMO INHIBIDORES DE PROTEíNA QUINASAS, COMPOSICIONES FARMACÉUTICAS QUE LAS CONTIENEN Y SU USO EN LA PREPARACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR LA ACTIVIDAD BASAL DE B-RAF. | |
| PE20130012A1 (es) | Derivados de pirazol como inhibidores de jak | |
| AR039648A1 (es) | Compuestos de aril cetona pirrolo triazina utiles como inhibidores de cinasa y las composiciones farmaceuticas que las contienen | |
| NO20033145L (no) | Purinderivater som purinergiske reseptorantagonister | |
| NZ533310A (en) | Benzimidazoles useful as protein kinase inhibitors | |
| MXPA05013349A (es) | Derivados de 2-amino-pirimidina como inhibidores de quinasa raf. | |
| DK1412354T3 (da) | Derivater af triazolylimidazopyridin og af triazolylpurinerne, der er egnede som ligander for adenosin A2a?-receptoren og deres anvendelse som medikamenter | |
| TW200716528A (en) | Cyclopropanecarboxamide derivatives | |
| EA201000101A1 (ru) | Производные пиримидина 934 | |
| PE20091243A1 (es) | Compuesto heterociclico fusionado | |
| TW200612936A (en) | Indole derivatives | |
| CY1109376T1 (el) | Παραγωγα υδαντοϊνης χρησιμα ως αναστολεις μεταλλοπρωτεϊνασης | |
| UY29312A1 (es) | Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones | |
| AR035945A1 (es) | Derivados de piperacina, su uso en la preparacion de medicamentos, procedimiento para la preparacion de dichos compuestos, composiciones farmaceuticas que comprenden dichos compuestos, y metodo para preparar dichas composiciones | |
| EA200500690A1 (ru) | Новые соединения пиридопиримидинона, способ их получения и фармацевтические композиции, которые их содержат | |
| DE60014404D1 (de) | Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha | |
| NO20075617L (no) | 4-fenyl-5-okso-1,4,5,6,7,8-heksahydrokinolinderivater for behandling av infertilitet | |
| DE60014394D1 (de) | Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha | |
| EA200500717A1 (ru) | Новые соединения имидазопиридина, способ их получения и фармацевтические композиции, которые их содержат |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |